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Abstract
Hypophosphatasia (HPP) is an inherited systemic bone disease caused by the deficiency 
of tissue-nonspecific alkaline phosphatase (TNAP). HPP is classified into six forms and 
the symptoms of HPP vary depending on the form. The pathophysiology of HPP is basi-
cally due to a defect of bone mineralization. TNAP is encoded by the ALPL gene, and 
the TNAP protein expressed in bone, kidney, liver, and neuronal cells and is linked to 
the cell membrane via a glycosylphosphatidylinositol anchor. TNAP is an ectoenzyme 
hydrolyzing phosphate compound such as inorganic pyrophosphate. TNAP plays an 
important role in mineralization of hard tissues. Defect of mineralization process causes 
hypomineralization of hard tissues, which leads to rickets or osteomalacia and dental 
manifestations. In addition, hypomineralization of the ribs results in respiratory failure 
in the severe forms, which is the main cause of death. Inheritance of HPP is autosomal 
recessive, but autosomal dominant cases have been reported in the milder forms. To date, 
a total of 335 mutations in the ALPL gene have been reported, and mutation sites are 
scattered throughout the gene. Recent development of enzyme replacement therapy has 
opened up a new vista on the treatment of this previously untreatable disease.
Keywords: hypophosphatasia, alkaline phosphatase, mineralization, bone, enzyme replace- 
ment therapy
1. Introduction
Hypophosphatasia (HPP; Online Mendelian Inheritance in Man (OMIM) #241500,241,510, 
146,300) is an inherited systemic bone disease that is due to a deficiency of tissue-nonspe-
cific alkaline phosphatase (TNAP) [1–3]. The first case of HPP was reported by the Canadian 
pediatrician John Campbell Rathbun in 1948 as a new developmental anomaly [4]. That case 
was an infantile form, and the patient’s mutations were identified 50 years later using DNA 
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of the surviving parents as a compound heterozygote of p.A114T and p.D294A [5]. Since 
then, a total of 335 mutations in the gene for TNAP (the ALPL gene) have been reported [6]. 
The symptoms of HPP vary and are classified into six HPP forms [1, 2]. The pathophysiol-
ogy of HPP is basically due to a defect of bone mineralization. In severe forms, the patients 
show skeletal manifestations and respiratory failure derived from costal bone insufficiency, 
whereas in the mildest forms, they show only dental manifestations [1]. Recent development 
of enzyme replacement therapy (ERT) has opened up a new vista on the treatment of this 
previously untreatable disease [7].
2. TNAP: gene, structure of the protein, and its function as an enzyme
There are four human alkaline phosphatase (ALP) isoenzymes (Table 1): TNAP, placental 
alkaline phosphatase (PLAP), intestinal alkaline phosphatase (IAP), and germ cell ALP 
[8, 9]. The latter three ALPs are tissue-specific and are expressed in the placenta, intes-
tine, and germ cells (embryonic and cancer cells), respectively [9]. TNAP, also known as 
the liver/bone/kidney (LBK) alkaline phosphatase, is expressed ubiquitously; liver, bone, 
kidney, neuronal cells, and white blood cells in particular are tissues that show marked 
expression [10].
Human TNAP is encoded by the ALPL gene that is located on the short arm of chromo-
some 1 (1p36.1–34). The coding region of the gene is approximately 1.5 kb in length, and 
it is extended over more than 50 kb of genomic DNA [11]. The ALPL gene consists of 12 
exons of which exons 2–12 are coding exons and there exist two alternative noncoding 
exons 1 (bone type and liver type) [12, 13]. The promoter region of the gene includes a 
TATA box, an Sp1 binding site, and a retinoic acid responsive element (RARE) [14, 15]. 
Common name Protein name Gene Chromosomal 
location
Sites of 
expression
Function
Tissue-nonspecific (liver/
bone/kidney)
TNAP 
(TNSALP)
ALPL 1p36.1–34 Ubiquitous Mineralization 
entrance of pyridoxal 
phosphate into the 
neuronal cells
Intestinal IAP ALPI 2q34–37 Intestine Degradation of LPS* 
lipid absorption
Placental PLAP (PAP) ALPP 2q34–37 Placenta Degradation of 
LPS* (?)
Germ cell (placental like) — ALPP2 2q34–37 Germ cells
Cancer cells
*Lipopolysaccharides.
Table 1. Isoenzymes of human ALP.
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Retinoic acid regulates the expression of TNAP via RARE [15], whereas another fat-soluble 
vitamin, active vitamin D (1,25-dihydroxycholecalciferol), regulates the expression of 
TNAP by modification of the stability of TNAP mRNA [16]. Furthermore, phosphates 
derived from ALP enzymatic activity are considered to regulate TNAP expression [17]. 
Epigenetic regulation by methylation of some of the promoter regions of the gene has been 
reported [18]. However, the precise regulatory mechanism of the ALPL gene regulation, 
especially its tissue-specific regulation, is not known. On the other hand, the genes encod-
ing tissue-specific ALPs are located on the long arm of chromosome 2 and have a more 
compact gene structure [19–22].
The TNAP protein, which has a molecular weight of approximately 80 kDa, is linked to 
the outer cell membrane through a glycosylphosphatidylinositol (GPI) anchor [9]. The 
TNAP protein is initially synthesized as a 66 kDa peptide, and then O- and N-glycosides are 
attached in the endoplasmic reticulum. Eventually, TNAP is localized on the outer mem-
brane of the cells via a GPI anchor [23]. This GPI anchor is added after hydrophobic amino 
acid residues at the C-terminus are eliminated. The GPI anchor consists of an ethanolamine 
phosphate, three residues of mannose, a glucosamine, and a phosphatidylinositol [9]. The 
precise amino acid residue in TNAP to which the GPI anchor is added has not been elu-
cidated, whereas it is known to be an aspartate residue (D484) in PLAP [24, 25]. An active 
enzyme consists of a dimer and acts as an ectoenzyme. Approximately 58% of the amino acid 
residues in human TNAP sequences are conserved among mammalian ALPs [26]. On the 
other hand, approximately 90% of the amino acid residues are conserved among mamma-
lian TNAPs, which allow prediction of missense mutations responsible for HPP [26]. Since 
the three dimensional structure of TNAP has not been solved, a simulation model based on 
human PLAP or mouse IAP is used to discuss TNAP structure [27–29]. The active site of the 
enzyme comprises a catalytic serine residue (S92 in the human PLAP), two Zn2+-binding 
sites, and an Mg2+-binding site. Ca2+ is also necessary as a cofactor. The crown domain is 
characteristic of mammalian ALPs and is considered to interact with extracellular proteins 
including collagen [30]. There are also isoforms of TNAP itself that depend on the tissue ori-
gin. Since these isoforms have different O-linked sugar chains, they show different patterns 
on the electrophoresis. [9, 31].
The systematic name of ALP is orthophosphoric-monoester phosphohydrolase [alkaline 
optimum] (EC 3.1.3.1) that hydrolyzes monophosphate esters, and the optimal pH is 
between 8 and 10 [9]. Inorganic pyrophosphate (PPi) and pyridoxal 5′-phosphate (PLP) 
are considered to be natural substrates of the enzyme [32]. PPi is an inhibitor of hydroxy-
apatite formation, which is essential for bone mineralization. PLP is an active vitamin B6 and is necessary in neuronal cells for the biosynthesis of γ-aminobutyric acid (GABA), 
which acts as an inhibitory neurotransmitter. PLP on the outside of neuronal cells must be 
dephosphorylated by TNAP at the cell membrane before it can enter the neuronal cells, 
and it is then be rephosphorylated within the neuronal cells [32, 33]. In laboratory testing, 
ALP enzymatic activity is usually estimated using p-nitrophenylphosphate as an artificial 
substrate [9].
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3. Molecular process of mineralization and the role of TNAP in 
mineralization
Biomineralization in hard tissues including bone occurs in a two-step process [34]. 
Hypertrophic chondrocytes, osteoblasts, and odontocytes in the bone and dental tissues bud 
matrix vesicles (MVs) from the cell membrane [2, 35]. MVs are 50–200 nm in diameter and 
are enclosed by a membrane. MVs are a type of extracellular vesicles; however, the difference 
between MVs and exosomes, which are secreted by cells in the nonmineralized condition, is 
unclear [36]. TNAP is one of the most abundant proteins on the membrane of an MV [34]. 
The other proteins that are abundant in MVs are annexins A2, A5, and A6, Ca2+-ATPase, 
nucleotide pyrophosphatase phosphodiesterase 1 (NPP1), Pit-1 (a sodium-phosphate 
cotransporter), and PHOSPHO1, all of which have important roles in mineralization [9, 34]. 
Biologically, mineralization is defined as the deposition of hydroxyapatite (Ca10(PO4)6(OH)2) crystals among the collagen fibers. If this process is insufficient, extracellular spaces are not 
mineralized, which leads to the formation of an abnormal soft tissue called osteoid tissue. In 
the first step of the mineralization, hydroxyapatite is formed in an MV. The membrane lipids 
of the MV provide a source of phosphate; of these lipids, phosphatidylcholine and phos-
phatidylethanolamine are hydrolyzed by phospholipase C (PLC), yielding phosphocholine 
(PCho) and phosphoethanolamine (PEA), respectively [37]. Subsequently, PCho and PEA 
are hydrolyzed by PHOSPHO1, a cytosolic phosphatase abundant in MVs [38]. The phos-
phate transporter, Pit-1, provides another source of phosphate. On the other hand, calcium 
is incorporated into MVs via an annexin calcium channel, which consists of annexins A2, A5, 
and A6 [34, 35]. When the concentration of calcium phosphate rises beyond the solubility of 
calcium phosphate, hydroxyapatite crystal formation begins. Subsequently, hydroxyapatite 
crystals penetrate the MV membrane and elongate in the extracellular space [34, 35]. For the 
elongation of hydroxyapatite, calcium and phosphate should be provided by the extracel-
lular space. Although calcium ions may be abundant in this milieu, phosphate is provided 
mainly by the TNAP on the MV membrane, which hydrolyzes PPi to yield inorganic phos-
phate (Pi) [2, 8, 34]. This hydrolysis by TNAP has dual roles; it supplies a source of phosphate 
for hydroxyapatite formation and degrades an inhibitor of hydroxyapatite formation (PPi). 
Ultimately, formed hydroxyapatite crystals deposit among collagen fibers, and mineraliza-
tion is complete (Figure 1). Although the crown domain of TNAP can bind collagen and is 
suggested to have a role in hydroxyapatite deposition, it has not been elucidated whether 
TNAP plays a direct role in hydroxyapatite deposition.
Extracellular PPi is formed by NPP1 on the MV membrane by hydrolysis of ATP and also 
provided by a membrane transporter of PPi, ANKH (the human homolog of ANK, the mouse 
progressive ankylosis gene product). Therefore, mineralization is regulated by the balance of 
the activities of these three molecules: TNAP, NPP1, and ANKH [9, 39, 40], Experiments using 
mice with knockout of these three genes showed that loss of activity of NPP1 or ANKH leads 
to hypercalcification (ectopic calcification of aorta and/or vertebrae and joints), whereas that 
of TNAP causes hypomineralization [41].
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4. Clinical features of HPP including laboratory tests
HPP is classified into six forms depending on the onset age and the clinical severity 
(Table 2): perinatal (lethal) form, perinatal benign form, infantile form, childhood form, 
adult form, and odontohypophosphatasia [3]. The perinatal form occurs in utero and exhib-
its the most severe manifestations. Patients are stillborn or die during the early postnatal 
period. They show hypomineralization of the cranial bone and shortened and deformed 
limbs during gestation, which are easily revealed by ultrasonic examination. The hypo-
mineralization of bones causes a membranous cranium and early craniosynostosis as 
well as musculoskeletal disorder after birth. The ribs are also hypomineralized, leading 
to respiratory failure after birth, which often requires respiratory aid. Failure of respira-
tory management often causes respiratory infections, which are the main cause of death. 
Epileptic seizures sometimes occur due to a deficit of PLP in neuronal cells, since PLP 
needs TNAP to enter neuronal cells. A deficit of PLP in neuronal cells causes a decrease in 
the inhibitory neurotransmitter GABA, leading to epileptic seizures. The perinatal benign 
form is a recently reported form [42]. Although the symptoms are recognized in gesta-
tion, prognosis is good and nonlethal. The infantile form occurs before 6 months of age 
and also shows severe manifestations. Patients display rickets and deformity of ribs and 
limbs, and fail to thrive. They also exhibit respiratory failure due to hypomineralization 
of the ribs, which requires respiratory aid. Recent progress in respiratory management 
elongates their lifespan. In addition, they often show hypercalcemia and hypercalciuria, 
leading to nephrocalcinosis. The childhood form shows manifestations after 6 months 
of age, whose symptoms are milder and not life-threatening. Patients show deformity 
of limbs, delayed walking, waddling gait, and muscle weakness. Craniosynostosis and 
Figure 1. Mineralization process focusing on the matrix vesicle.
Hypophosphatasia: A Systemic Skeletal Disorder Caused by Alkaline Phosphatase Deficiency
http://dx.doi.org/10.5772/intechopen.70597
105
high intracranial pressure sometimes occur. These patients also show premature loss of 
deciduous teeth due to failure of cementum formation [43]. Radiologically, childhood 
form patients exhibit a characteristic tongue-like radiolucent projection from the rachitic 
growth plate into the metaphysis due to a focal bone defect at the ends of long bones [1, 
3]. The adult form occurs during middle age. Although the natural history of the adult 
form has not been well characterized, patients sometimes have a history of rickets and/
or premature loss of deciduous teeth [44]. In the adult form, osteomalacia develops with 
pain associated with often recurring metatarsal stress fractures. In some patients, calcium 
pyrophosphate dehydrate crystals are deposited on articular cartilage due to an increase 
in concentrations of endogenous PPi [1]. Odontohypophosphatasia manifests only den-
tal symptoms such as premature loss of deciduous teeth without skeletal symptoms 
due to rickets or osteomalacia.
Form Inheritance 
pattern
Onset Symptoms Prognosis
Perinatal AR In utero Deformity of extremities Lethal
Membranous cranium
Respiratory failure
Epileptic seizures
Perinatal benign AR or AD In utero Rickets Benign
Infantile AR After birth Rickets, Craniosynostosis Mostly lethal
Before 6 months 
of age
Respiratory failure
Failure to thrive
Epileptic seizures
Premature loss of deciduous 
teeth
Childhood AR or AD After 6 months 
of age
Rickets Benign
Musculoskeletal weakness
Premature loss of deciduous 
teeth
Adult AR or AD Middle age Osteomalacia Benign
Stress fractures
Odontohypophosphatasia AR or AD Premature loss of deciduous 
teeth
Benign
Dental caries
AR: autosomal recessive, AD: autosomal dominant.
Table 2. Clinical features of hypophosphatasia.
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General
 Failure to thrive
 Poor feeding
 Weakness
Skeletal
 Hypomineralization
 Rickets/osteomalacia
 Short, deformed limbs
 Membranous cranium
 Craniosynostosis
 Deformed ribs
 Skeletal pain
 Short statue
Muscular
 Muscle weakness
 Gait disturbances; delayed walking, waddling gait
Neuronal
 Epileptic seizures (pyridoxine dependent)
 Irritability
Respiratory
 Respiratory failure
Renal
 Nephrocalcinosis
Dental
 Premature loss of deciduous teeth
 Dental caries
Blood examination
 Reduced serum ALP
 Elevated plasma PPi, PLP and PEA
 Elevated plasma Ca2+
Urinalysis
 Elevated urine PEA
 Elevated urine Ca2+
Different presentation of symptoms is exhibited depend on the forms.
Table 3. Signs and symptoms of HPP.
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A common histopathological feature of HPP is hypomineralization of bone and teeth [1]. 
Extracellular hydroxyapatite crystals are reduced, although mineralization occurs within the 
MV, because PHOSPHO1 acts in the MV. Elongation of hydroxyapatite is impaired. Osteoid 
tissues are increased in bone, which contains nonmineralized extracellular matrix, and they 
cause rickets or osteomalacia [45].
For all forms, a characteristic laboratory finding is low serum alkaline phosphatase activity, 
in which the bone isozyme is reduced [1]. In addition, the natural enzyme substrates, plasma 
PPi and PLP are elevated. Urine PEA is also elevated, although it is doubtful whether this 
compound is a natural substrate of TNAP. However, because urine PEA is easy to evaluate by 
using high-performance liquid chromatography (HPLC), the measurement of PEA is widely 
used for the diagnosis [2]. The combination of low ALP activity with elevated PPi or PEA is 
strong evidence for HPP. In some milder cases, however, an increase in PEA is not shown, 
and, in some cases, PEA is slightly elevated in carriers [46]. Signs and symptoms of HPP are 
summarized in Table 3.
5. Genetic aspect of HPP
5.1. Inheritance of HPP
HPP is an autosomal recessive inherited disease [1]. Carriers usually do not exhibit any mani-
festations. Sometimes, however, carriers show subnormal serum ALP activity and slightly 
higher urine PEA values [2, 46]. The penetrance differs among forms. In some milder cases, 
an autosomal dominant cases have been reported [47, 48], and the dominant negative effect 
accounts for some autosomal dominant cases [48]. In addition, different severity of the symp-
toms within the same family has been reported [49, 50], suggesting the involvement of epi-
genetic mechanisms.
5.2. Prevalence of HPP
The prevalence of HPP was estimated as 1 in 100,000 live births in the Toronto area in Canada, 
where the first case was found [51]. In Manitoba, Canada, the prevalence is higher in the 
Mennonite group, being 1 in 2500, according to a founder effect of a particular mutation [52]. 
In Europe, the prevalence of severe cases is estimated as 1 in 300,000 [53], whereas in Japan it 
is 1 in 450,000 for patients who have the c.1559delT allele [46]. This particular allele is a severe 
allele and is characteristic of Japanese families (46.8% of Japanese patients with HPP have this 
deletion allele) [46].
5.3. Genetic diagnosis
When HPP is suspected, collection of the family history and the making of a pedigree are 
important for genetic counseling [54]. Clinical diagnosis can be done by laboratory biochemi-
cal examinations and ultrasonic and radiographic findings. Definitive diagnosis is performed 
by genetic testing. Genomic DNA of the patient is amplified, and the nucleotide sequences 
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are determined. Polymerase chain reaction-single-strand conformation polymorphism (PCR-
SSCP), PCR-denaturing gradient gel electrophoresis (PCR-DGGE), and high-resolution melt-
ing curve analysis (HRM) methods used to be employed for this purpose, but direct nucleotide 
sequencing may be the most effective current method of analysis. Once the mutation of the 
proband is determined, the inheritance can be pursued by testing the parents’ DNA, which 
makes it possible to give a genetic counseling, because the inheritance pattern of HPP is basi-
cally Mendelian inheritance [54, 55]. However, as mentioned above, the same mutation can 
result in different phenotypes in some families. In addition, a rare case of paternal unipa-
rental isodisomy has been reported [56]. Once a genetic diagnosis is established, enzymatic 
activity and mineralization activity can be evaluated [57]. An expression plasmid contain-
ing the mutant cDNA is transfected into U2OS cells, which are osteoblast-like cells that lack 
ALP activity. The cells are then cultured for an appropriate period, and enzymatic activity 
is estimated. For the mineralization assay, the transfected cells are cultured in a mineraliza-
tion medium that contains β-glycerophosphate as an artificial substrate for TNAP, with or 
without ascorbic acid. After about 5 days of culture, mineralization is estimated by Alizarin 
Red S staining [57].
5.4. Prenatal diagnosis
Prenatal diagnosis by ALP enzymatic assay or by immunological detection using amniotic 
fluid and chorionic villus has been reported, but their diagnostic value is low [3] because of 
contamination of fetal intestinal ALP and maternal ALP. HPP can be diagnosed using ultra-
sonography and radiography during the second trimester, but the differential diagnosis is 
complicated. DNA-based diagnosis using chorionic villus is accurate if information about the 
nucleotide sequences within the family has been obtained [54, 58]. However, prediction of 
the prognosis of the disease is not easy, because of the fact that the same mutations can cause 
different phenotypes even in the same family. In addition, ethical considerations including 
genetic counseling are very important when prenatal genetic diagnosis is performed [54].
6. Mutations in the ALPL gene
To date, a total of 335 mutations in the ALPL gene have been reported [6]. The TNAP gene 
mutations’ databases (http://www.sesep.uvsq.fr/03_hypo_mutations.php) of the University 
of Versailles-Saint Quentin en Yvelines provide up-to-date information regarding mutations 
[55]. Almost all of these mutations are located within the exons, although some mutations 
are in the promoter region, exon-intron boundaries and introns. In addition, over 70% of the 
mutations are missense mutations, 11% are small deletions, 6% are splicing mutations, 5% 
are nonsense mutations, 3% are small insertions, and 3% are large deletions [6]. Only one 
regulatory mutation has been reported [59]. Many of the patients are compound heterozy-
gotes. Generally, the interaction between the mutant alleles determines the phenotypes of 
the patients. Residual activities of mutant TNAPs influence the enzymatic activity and the 
mineralizing activity of the compound heterozygotes. However, the relationships of geno-
type and phenotype are rather complicated, and the phenotypes are not always estimated 
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from the combination of the genotypes. Mutation sites are scattered throughout the gene, but 
there are some “hot spots.” In Caucasian patients, p.E191K (a moderate allele with a domi-
nant negative effect) and p.D378V (a severe allele) are frequent mutations [60, 61], whereas 
c.1559delT (pL520RfsX86; a severe allele) and p.F327L (a moderate allele) are frequent in 
Japanese patients [62, 63]. c.1559delT also has founder effects, and the frequency of c.1559delT 
is mentioned above [46, 62].
7. Structure and function of mutant TNAP
Mutation sites of TNAP proteins are classified by its domain structure [30]. Severe pheno-
types are associated with the mutations that are located in the active site and its vicinity, the 
homodimer interface, the crown domain, and the calcium-binding domain. Mutations in the 
active site valley (the entry site of the substrate into the active site) resulted in less severe 
phenotypes [30]. Mutations in the other regions of the protein are inclined to show residual 
enzymatic activity and are, therefore, milder phenotypes.
Because most of the patients are compound heterozygotes, the residual activity and pheno-
type are determined by the interaction of two mutant proteins [55]. In some cases, especially 
in autosomal dominant cases, dominant negative mechanisms are suggested, in which cases 
the mutant proteins affect the function of the wild-type enzymes [48]. Those interactions have 
not been precisely elucidated and need to be explored in more detail in order to reveal the 
genotype–phenotype interrelationships and pathophysiology of HPP.
8. Treatment of HPP based on the pathophysiology of the disease
There have been several trials for the treatment of HPP. Respiratory aid somehow succeeds 
in saving life in the perinatal and the infantile forms, although it is a symptomatic treatment. 
Other symptomatic treatments are diet therapies, including calcium restriction and vitamin 
D supplementation, and surgical operations for bone fractures and craniosynostosis [1]. In 
terms of treatment based on the pathophysiology of HPP, ERT has been attempted. Whyte 
et al. used the serum of Paget’s disease patients who exhibited a high level of TNAP for 
enzyme replacement [64]. Infusion of PLAP has also been attempted based on the observation 
that, when the patients with mild forms become pregnant, which causes a high serum ALP 
level according to an increase in PLAP, they sometimes show improvement of symptoms. 
Those ERT attempts, however, failed to improve the symptoms [3]. Bone marrow transplan-
tation (BMT) and mesenchymal cell transplantation have also been attempted. Those trials 
showed a slight improvement but an insufficient effect [65]. Successful ERT was reported in 
2012, in which bioengineered TNAP was administered [7]. The C-terminal membrane-bound 
region of human TNAP was eliminated and replaced with the Fc region of human IgG and 
deca-aspartate sequences [66]. This bioengineered TNAP is, therefore, soluble, can be easily 
purified using the Fc region, and has high affinity for hydroxyapatite through acidic peptides 
such as deca-aspartate [66]. Before the trial, an animal experiment using the bioengineered 
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TNAP in a knockout mouse (Akp2−/−; AKP2 is the mouse homolog of the ALPL) that is a good 
mimic of the perinatal form of HPP, showed elongation of life and improvements in bone and 
dental defects without respiratory failure [66, 67]. The clinical trial with the bioengineered 
TNAP (ENB-0040; asfotase alfa) was conducted with five perinatal and six infantile patients 
[7]. It was administered first as a single intravenous infusion of 2 mg/kg, which was then 
followed by subcutaneous injections three times per week at a dose of 1 mg/kg for 48 weeks. 
With the exception of one case who died of respiratory failure that was unrelated with asfo-
tase alfa, the recruited patients showed improvements in rickets and respiratory failure [7]. 
Asfotase alfa (StrensiqST; Alexion Pharmaceuticals, Inc.) was approved in Japan, the EU, 
Canada, and the USA in that order in 2015 [2]. Asfotase alfa has dramatically changed the 
treatment of HPP [68]. Asfotase alfa is indicated for the treatment of patients with perinatal-, 
infantile- and juvenile-onset HPP [69], in which juvenile-onset HPP means almost the same as 
the childhood form. The current protocol of the recommended administration is subcutane-
ous injection six times a week at a dose of 1 mg/kg or three times a week at 2 mg/kg, and the 
maximal volume of injection is 1 ml [69]. The half-life of asfotase alfa is 5 days in the case of 
subcutaneous administration. The most common adverse reactions (≥ 10%) are injection site 
reactions, lipodystrophy, ectopic calcifications, and hypersensitivity reactions. Patients with 
HPP are at increased risk for developing ectopic calcifications, especially of the eye including 
the cornea and conjunctiva, and the kidneys (nephrocalcinosis). Although ectopic calcifica-
tion of the blood vessels has not been reported, it is conceivable that long -term administra-
tion may cause medial artery calcification. Medial artery calcification or Mönckeberg-type 
calcification is often shown as a lethal complication in chronic kidney disease (CKD) patients 
[70]. In CKD patients, hyperphosphatemia triggers transformation of smooth muscle cells 
in the media into osteoblastic cells that express elevated TNAP, which then stimulates calci-
fication in the medial artery by a mechanism similar to that of bone mineralization [71, 72]. 
Asfotase alfa is still not indicated for milder form HPP patients. In this regards, the natu-
ral history of the adult form has not been well elucidated [44], and more study is needed. 
Similarly, odontohypophosphatasia may be still underdiagnosed, because dentists usually 
do not evaluate the serum ALP value. There should be more investigation into the feasibility 
of using asfotase alfa for those milder forms.
9. Future perspective
Although current ERT has drastically changed the treatment of HPP, many problems are 
indicated regarding asfotase alfa administration. First of all, two or three injections per week 
are needed for this ERT treatment, which burdens patients with injections and parents with 
administration fees. The interval between injections can be elongated by introducing some 
modifications into the enzyme preparation. Other possible therapies are bone marrow stem-
cell transplantation and/or combination therapy of such transplantation with ERT. Another 
possible trial is a trial of gene therapy. Using viral vectors, gene therapy was successfully 
used to treat knockout mice (AKP2−/−) [73, 74]. Since a viral vector containing ALPL cDNA 
that is injected into blood cannot maintain an effective concentration, gene therapy in com-
bination with stem-cell transplantation (ex vivo gene therapy) may be more effective [75]. 
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Once gene-transferred stem cells are transplanted, no other injection may be necessary [2]. 
Although gene therapy seems to be a promising procedure, results have so far only been 
obtained for mouse models, and its feasibility and safety in humans must be investigated.
10. Conclusions
HPP is a systemic skeletal disorder that is caused by TNAP deficiency. Human TNAP is one 
of the four isoenzymes of alkaline phosphatase and is expressed ubiquitously. The TNAP 
protein is linked to the outer membrane of cells via a GPI anchor and works as an enzyme in a 
homodimer state. TNAP is essential for biomineralization; it is located on the MV membrane 
and plays a role in the elongation of hydroxyapatite crystals into the extracellular space.
HPP is classified into six forms and clinical severity varies among the forms. Hypomineralization 
of hard tissues is a common feature of HPP. In the severe forms, patients show rickets and 
respiratory failure that cause death. Milder forms exhibit musculoskeletal disorder or teeth 
problems. Although low serum ALP activity and an elevated urine PEA value are character-
istic of HPP, genetic diagnosis is the definitive diagnosis. ERT using a genetically modified 
enzyme (asfotase alfa) opens up a new vista in the therapy of HPP, especially for severe forms 
of HPP. Although asfotase alfa has drastically changed the treatment of HPP, there remain 
still several problems with its use that need to be resolved.
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